Illumina, Inc. ILMN
270.00
(3.90)
(1.42%)
as of 25 Sep
- Market cap
- $41.3B
- P/E
- 50.4×
Follow ILMN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Illumina, Inc. (ILMN) Net margin
Illumina, Inc.'s net margin over the twelve months to 30 June 2026 was 18.4%, down 1.2 percentage points from fiscal 2025 (19.6%). Over the past ten years it has ranged from −96.1% (fiscal 2022) to 28.3% (fiscal 2019); the current reading is higher than 55% of that period. That is above the Diagnostics & Research industry median of −6.37% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 19.6% | 47.54 |
| FY2024 | −28.0% | (2.19) |
| FY2023 | −25.8% | 70.29 |
| FY2022 | −96.1% | (112.91) |
| FY2021 | 16.8% | (3.41) |
| FY2020 | 20.3% | (8.03) |
| FY2019 | 28.3% | 3.50 |
| FY2018 | 24.8% | (1.60) |
| FY2017 | 26.4% | 7.07 |
| FY2016 | 19.3% | (1.50) |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 17.9% | 5.58 |
| Mar 2026 | 12.3% | (16.54) |
| Dec 2025 | 28.8% | 14.98 |
| Sep 2025 | 13.8% | (8.35) |
| 42 more quarters | Free account |
Against its own ten years
Low −96.1%
High 28.3%
Ten-year median
19.6%
Current reading's percentile
55
Net margin against peers
| Company | Net margin |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 25.0% |
| MTD Mettler-Toledo International, Inc. compare | 21.9% |
| A Agilent Technologies, Inc. compare | 19.5% |
| ILMN Illumina, Inc. | 18.4% |
| DGX Quest Diagnostics Incorporated compare | 9.15% |
| IQV IQVIA Holdings Inc. compare | 8.10% |
| WAT Waters Corporation compare | 3.59% |
| NTRA Natera, Inc. compare | −7.11% |
| GH Guardant Health, Inc. compare | −38.3% |
| Diagnostics & Research industry median | −6.37% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on ILMN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement